Low LeverageImmunicum's extremely low debt level and materially reduced total debt improve financial flexibility and lower refinancing risk. For a cash-burning biotech, low leverage lengthens runway, supports continued R&D investment, and reduces near-term solvency pressure over coming months.

Improving Cash OutflowsOperating and free cash flow have become less negative versus prior years, indicating the company is reducing burn or improving cash management. If sustained, this structural improvement extends operational runway and reduces near-term financing needs over the next 2–6 months.

Narrowing Net LossesThe reduction in headline net loss versus the prior year suggests improving cost control or progress in operations. A persistent trend of narrowing losses supports better cash conversion prospects and reduces the gap to required funding outcomes over the medium term.

Bears Say

Persistent Cash BurnLarge negative operating and free cash flow indicate the business does not self-fund and continues to deplete resources. This structural cash burn necessitates external financing or partnerships, raising dilution and execution risk until cash generation reverses or new capital is secured.

Large Ongoing LossesMaterial and persistent net losses reflect a lack of operating profitability and weak margins. This undermines returns on equity, constrains reinvestment capacity, and increases reliance on capital markets or partners to sustain development programs over the coming months.

Weak, Inconsistent RevenueVery small and declining revenue versus prior year shows limited commercial traction and inconsistent top-line generation. A weak revenue base prolongs the path to profitability, increases funding dependence, and reduces ability to leverage revenues to cover fixed R&D and G&A costs.

IMMU FAQ

What was Immunicum AB’s price range in the past 12 months?

Immunicum AB lowest stock price was kr4.17 and its highest was kr10.98 in the past 12 months.

What is Immunicum AB’s market cap?

Immunicum AB’s market cap is kr295.15M.

When is Immunicum AB’s upcoming earnings report date?

Immunicum AB’s upcoming earnings report date is May 08, 2026 which is in 79 days.

How were Immunicum AB’s earnings last quarter?

Immunicum AB released its earnings results on Feb 11, 2026. The company reported -kr0.74 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.74.

Is Immunicum AB overvalued?

According to Wall Street analysts Immunicum AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Immunicum AB pay dividends?

Immunicum AB does not currently pay dividends.

What is Immunicum AB’s EPS estimate?

Immunicum AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Immunicum AB have?

Immunicum AB has 62,584,580 shares outstanding.

What happened to Immunicum AB’s price movement after its last earnings report?

Immunicum AB reported an EPS of -kr0.74 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.055%.

Which hedge fund is a major shareholder of Immunicum AB?

Currently, no hedge funds are holding shares in SE:IMMU

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Immunicum AB

Mendus AB (publ), a biopharmaceutical company, develops immunotherapies and relapse vaccines for the treatment of cancer. Its lead product is ilixadencel, which is in Phase II MERECA clinical trial for the treatment of kidney cancer; and Phase I/II clinical trial to treat liver cancer and gastrointestinal stromal tumors. The company's products also comprise DCP-001, which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia; and Phase I/II ALISON clinical trial for the treatment of ovarian cancers. It has a research collaboration with PCI Biotech Holding ASA for novel cancer vaccination treatment; and with Icahn School of Medicine at Mount Sinai. The company was formerly known as Immunicum AB (publ) and changed its name to Mendus AB (publ) in June 2022. Mendus AB (publ) was incorporated in 2002 and is headquartered in Stockholm, Sweden.